Efficacy of atorvastatin therapy in ischaemic heart disease - Effects on oxidized low-density lipoprotein and adiponectin

Journal of International Medical Research

Volumn 35, Issue 4, 2007, Pages 534-539

  Miyagishima, K ^a   Hiramitsu, Shinya ^a   Kato, S ^a   Kato, Y ^a   Kitagawa, F ^b   Teradaira, R ^c   Shinohara, R ^d   Mori, K ^a   Kimura, H ^a   Ueda, T ^a   Ohtsuki, M ^a   Morimoto, S ^a   Hishida, H ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d MEIJO UNIVERSITY   (Japan)

Author keywords

Adiponectin; Anti atherosclerotic effects; Atorvastatin; Ischaemic heart disease; Oxidized low density lipoprotein; Serum lipids

Indexed keywords

ADIPONECTIN; ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; MALE; MYALGIA; PROTEIN BLOOD LEVEL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34547887274     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500413     Document Type: Article

References (19)

1. Nissen SE, Tuzcu EM, Schoenhagen P, et al: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis - A randomised controlled trial. JAMA 2004; 291: 1071-1080.
2. Cannon CP, Braunwald E, McCabe CH, et al: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
3. Grundy SM, Cleeman Jl, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239.
4. Pischon T, Girman CJ, Hotamisligil GS, et al: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-7737.
5. Matsuzawa Y, Funahashi T, Kihara S, et al: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
6. Jonkers IJ, Mohrschladt MF, Westendorp RG, et al: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002; 112: 275-280.
7. Paolisso G, Barbagallo M, Petrella G, et al: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150: 121-127.
8. Libby P, Aikawa M: Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 2003; 26(suppl 1): I11-I14.
9. Shinohara R, Kitagawa F, Fujita T, et al: Development and application of a simple and easy method for the determination of oxidized LDL and oxidized Lp(a). J Anal Bio-Sci 2005; 28: 433-437.
10. Sever PS, Dahlöf B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
11. Steinberg D: Lewis A Conner Memorial Lecture - oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062-1071.
12. Maeda K, Okubo K, Shimomura I, et al: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
13. Mason RP, Walter MF, Jacob RF: Effects of HMG-CoA reductase inhibitors on endothelial function - role of microdomains and oxidative stress. Circulation 2004; 109 (suppl II): II34-II41.
14. Ouchi N, Kihara S, Arita Y, et al: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
15. Ouchi N, Kihara S, Arita Y, et al: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.
16. Arita Y, Kihara S, Ouchi N, et al: Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898.
17. Fruebis J, Tsao T-S, Javorschi S, et al: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2004; 98: 2005-2010.
18. Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
19. Colhoun HM, Betteridge DJ, Durrington PN, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.